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Preliminary Epigenetic Results

Primer design & validation & PCR

Abstract
Background: Myoma, adenomyoma, and endometriosis are estrogendependent gynecologic diseases and result in reproductive dysfunction
and pelvic pain in women. However, these gynecologic diseases have a
complex and poorly understood etiology, involving both genetic and
environmental factors. Epigenetic alterations, heritable changes that
can modify gene expression without affecting genetic sequence, are
associated with the development and progression of numerous
pathological states and diseases. Therefore, there is great potential for
the use of epigenetics as biomarkers to better understand the earlystage biological responses and molecular mechanisms of gynecologic
diseases. We aimed to examine levels of global DNA and gene-specific
methylation, which are epigenetic alterations that could be associated
with development of gynecologic diseases, including myoma,
adenomyoma, and endometriosis.
Methods: We measured global DNA methylation (LINE-1) as well as
disease relevant gene-specific methylation (i.e. ER, PR, and aromatase)
using pyrosequencing assay. For this measurement, gene-specific
primers for the selected genes were designed using the Pyro-Mark
assay design software. Genomic DNAs from each tissue were
extracted, and underwent bisulfite modification to convert
unmethylated cytosine residues to uracil. A Pyromark Q96 MD was
used for all subsequent pyrosequencing. Samples were processed in
duplicates on plates with water controls. Percent methylation of a
sample was calculated by averaging all of the interrogated CpG sites.
Results: Different methylation levels of selected genes were measured
from myoma, adenomyoma, and endometriosis tissues. Our obtained
results suggest that epigenetic changes are involved in development of
different types of gynecologic diseases.

What is Epigenetics?
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Progesterone Receptor gene (PGR) is located on human chromosome 11. Using NCBI
and Ensembl databases, seven CpG sites were selected for primer design sequencing

NCBI database

Estrogen receptor gene (ESR) is located on human chromosome 11.
Using NCBI and Ensembl databases, two CpG sites were selected for
primer design sequencing.

A gradient PCR was used to determine ideal PCR thermocycler conditions for
each primer set prior to conducting pyrosequencing experiments
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Sequence (5’-3’)

Forward:
GGTTTTGTTAGGGATAGGATTT
Reverse:
CTACCTCCAACACCCCTTATAa
Sequencing: TGTTAGGGATAGGATTTTT
Forward:
AAGGGTTGAAGAGTGTGAGAA
Reverse:
ACTCAAAAACCCCCTCTACACTTCTTa
Sequencing: AGTGTGAGAAGTTAGAT

Biotin labeled primer

Primer sequences were determined using PyroMark
Assay Design software.
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Tissue-specific promoter methylation patterns will be observed in DNA of gynecologic
tissue of endometriosis patients.
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Promoter methylation status of DNA from different gynecologic
tissue. n=9-11 per tissue-type. Data expressed as mean ± SEM

Conclusions
• This study, using DNA methylation methods
including Bisulfite conversion, PCR and
pyrosequencing on a Pyromark-Q96,
supports that epigenetic changes could be
involved in development of different types
of gynecologic diseases.
• Promoter methylation of PGR and ESR
appears to be tissue-specific in different
gynecologic tissue DNA.
• These epigenetic differences could be useful
in biomarker development.

 Real time quantitative sequence data

• These epigenetic changes could have a
mechanistic influence on corresponding
gene expression
bitesizebio.com

Bisulfite conversion is an experimental method to distinguish methylated from nonmethylated cytosines through conversion of un-methylated cytosines to uracil.

Pyrosequencing Pyrograms
http://missinglink.ucsf.edu/lm/genes_and_genomes/methylation.html
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Methylation within gene promoter regions can
influence levels of gene expression.

Pyrosequencing using an ATP-driven light reaction
to generate a pyrogram used to measure %
methylation.
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Representative pyrograms for PGR and ESR. CpG % methylation is averaged across all CpG sites per assay.

• Further investigation of these methylation
patterns is needed.

Future Directions
• There is a potential clinical application of these
findings as biomarkers of gynecologic disease.
• Global methylation measurement as an overall
biomarker determination
• Measurement of promoter methylation in other
pro-inflammatory and gynecologic related genes.
• Measurement of global and gene-specific
methylation in blood.
• Isolation of RNA from tissues to conduct gene
expression experiments.

